Evidence strength in FDA premarket approval of cardiovascular devices.
Publication
, Journal Article
Kong, DF; Hasselblad, V; Krucoff, MW
Published in: JAMA
April 28, 2010
Duke Scholars
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
April 28, 2010
Volume
303
Issue
16
Start / End Page
1599 / 1600
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Uncertainty
- Risk
- Randomized Controlled Trials as Topic
- General & Internal Medicine
- Equipment and Supplies
- Device Approval
- Cardiovascular Diseases
- 42 Health sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Kong, D. F., Hasselblad, V., & Krucoff, M. W. (2010). Evidence strength in FDA premarket approval of cardiovascular devices. JAMA, 303(16), 1599–1600. https://doi.org/10.1001/jama.2010.511
Kong, David F., Vic Hasselblad, and Mitchell W. Krucoff. “Evidence strength in FDA premarket approval of cardiovascular devices.” JAMA 303, no. 16 (April 28, 2010): 1599–1600. https://doi.org/10.1001/jama.2010.511.
Kong DF, Hasselblad V, Krucoff MW. Evidence strength in FDA premarket approval of cardiovascular devices. JAMA. 2010 Apr 28;303(16):1599–600.
Kong, David F., et al. “Evidence strength in FDA premarket approval of cardiovascular devices.” JAMA, vol. 303, no. 16, Apr. 2010, pp. 1599–600. Pubmed, doi:10.1001/jama.2010.511.
Kong DF, Hasselblad V, Krucoff MW. Evidence strength in FDA premarket approval of cardiovascular devices. JAMA. 2010 Apr 28;303(16):1599–1600.
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
April 28, 2010
Volume
303
Issue
16
Start / End Page
1599 / 1600
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Uncertainty
- Risk
- Randomized Controlled Trials as Topic
- General & Internal Medicine
- Equipment and Supplies
- Device Approval
- Cardiovascular Diseases
- 42 Health sciences